Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
1(20.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(3)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06947928Phase 2Recruiting

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Role: lead

NCT06940440Phase 1Recruiting

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Role: lead

NCT04160065Phase 1Completed

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

Role: lead

NCT04853602Unknown

IFx-Hu2.0 Expanded Access Program

Role: lead

NCT04925713Phase 1Completed

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Role: lead

NCT03655756Early Phase 1Completed

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Role: lead

All 6 trials loaded